OCS
Oculis Holding AG$13.14
LiveJun 03, 2026
Market cap
$751.21M
52w range
11.70 – 34.48
P / E
—
EPS
—
Volume
1.68M
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on Oculis Holding AG’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Peers
No peer list available for OCS.
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.92% | -55.15% | -52.18% | -52.34% | -30.81% | -34.20% | -32.41% | +14.26% | +27.68% | +35.46% | +35.46% |
Aftermarket
LiveLast trade
$13.00
33 sh
Bid
$12.89
2 sh
Ask
$13.09
250 sh
Spread
$0.200
Sector & industry today
LiveSectors
- Healthcare+1.32%
- Financial Services+1.14%
- Industrials+0.68%
- Consumer Cyclical+0.59%
- Energy+0.52%
- Real Estate+0.46%
- Consumer Defensive+0.12%
- Basic Materials-0.28%
- Utilities-1.42%
- Communication Services-1.84%
- Technology-2.36%
Top industries (issuer's industry highlighted)
- Biotechnology-1.63%
- Rental & Leasing Services+5.32%
- Financial - Mortgages-4.41%
- Broadcasting-4.23%
- Investment - Banking & Investment Services-4.21%
- Software - Application-4.13%
- Auto - Recreational Vehicles+4.13%
- Software - Infrastructure-3.47%
- Information Technology Services-3.40%
- Department Stores+3.03%
- Silver-3.02%
- Apparel - Retail+2.95%
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $39.40 (+199.85%)
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraudgurufocus.com·Jun 03, 2026
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCSglobenewswire.com·Jun 02, 2026
- Oculis Reports Q1 2026 Financial Results and Provides Company Updateglobenewswire.com·May 11, 2026
- Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trialglobenewswire.com·May 07, 2026
- Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trialglobenewswire.com·May 07, 2026
- Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meetingglobenewswire.com·May 01, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|